[1]林芳芳,龚先琼.中药单体治疗酒精性肝损伤的研究现状[J].医学信息,2021,34(05):32-35,39.[doi:10.3969/j.issn.1006-1959.2021.05.010]
 LIN Fang-fang,GONG Xian-qiong.Advances in the Treatment of Alcoholic Liver Injury by Monomer of Traditional Chinese Medicine[J].Medical Information,2021,34(05):32-35,39.[doi:10.3969/j.issn.1006-1959.2021.05.010]
点击复制

中药单体治疗酒精性肝损伤的研究现状()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年05期
页码:
32-35,39
栏目:
综述
出版日期:
2021-03-01

文章信息/Info

Title:
Advances in the Treatment of Alcoholic Liver Injury by Monomer of Traditional Chinese Medicine
文章编号:
1006-1959(2021)05-0032-05
作者:
林芳芳龚先琼
(1.福建中医药大学第二临床医学院,福建 福州 351012; 2.福建中医药大学附属厦门中医院,福建 厦门 361009)
Author(s):
LIN Fang-fangGONG Xian-qiong
(1.the Second Clinical College,Fujian University of Traditional Chinese Medicine,Fuzhou 351012, Fujian,China; 2.Xiamen Traditional Chinese Medicine Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Xiamen 361009,Fujian,China)
关键词:
中药单体酒精性肝损伤苷类化合物黄酮类化合物
Keywords:
Chinese medicine monomerAlcoholic liver injuryGlycosidesFlavonoids
分类号:
R285.5
DOI:
10.3969/j.issn.1006-1959.2021.05.010
文献标志码:
A
摘要:
长期大量饮酒导致的酒精性肝损伤(ALI)是严重影响健康的疾病之一。随着ALI患病人数的增多,其已逐渐成为当前的研究热点。近年研究发现,中药单体在治疗ALI方面具有多途径、多靶点的优势,可能是潜在治疗该病的药物。本文主要对苷类化合物、黄酮类化合物及其他化合物等治疗ALI的相关研究进行综合,以期为临床治疗ALI提供参考。
Abstract:
Alcoholic liver injury (ALI) caused by long-term heavy drinking is one of the diseases that seriously affects health.With the increase in the number of patients with ALI, it has gradually become a current research focus.In recent years, studies have found that Chinese medicine monomer has the advantages of multiple pathways and multiple targets in the treatment of ALI, and may be a potential drug for the treatment of the disease.This article mainly summarizes the related researches on the treatment of ALI such as glycosides, flavonoids and other compounds, in order to provide reference for the clinical treatment of ALI.

参考文献/References:

[1]Kourkoumpetis T,Sood G.Pathogenesis of Alcoholic Liver Disease:An Update[J]Clin Liver Dis,2019,23(1):71-80. [2]蒋师放.NAMPT在对乙酰氨基酚诱导的急性肝损伤中作用的研究[D].重庆医科大学,2018. [3]Nagy LE,Ding WX,Cresci G,et al.Linking Pathogenic Mechanisms of Alcoholic Liver Disease With Clinical Phenotypes[J].Gastroenterology,2016,150(8):1756-1768. [4]Ding WX,Yang L.Alcohol and drug-induced liver injury:Metabolism,mechanisms,pathogenesis and potential therapies[J].Liver Res,2019,3(3-4):129-131. [5]Teschke R.Alcoholic Liver Disease:Alcohol Metabolism,Cascade of Molecular Mechanisms,Cellular Targets,and Clinical Aspects[J].Biomedicines,2018,6(4):106. [6]Lee DH,Kim DH,Hwang CJ,et al.Interleukin-32γ attenuates ethanol-induced l-iver injury by the inhibition of cytochrome P450 2E1 expression and inflammato-ry responses[J].Clin Sci(Lond),2015,128(10):695-706. [7]Ning C,Gao X,Wang C,et al.Hepatoprotective effect of ginsenoside Rg1 from Panax ginseng on carbon tetrachloride-induced acute liver injury by activating Nrf2 signaling pathway in mice[J].Environ Toxicol,2018,33(10):1050-1060. [8]Ning C,Gao X,Wang C,et al.Ginsenoside Rg1 protects against acetaminophen-induced liver injury via activating Nrf2 signaling pathway in vivo and in vitro[J].Regul Toxicol Pharmacol,2018(98):58-68. [9]Gao Y,Chu S,Shao Q,et al.Antioxidant activities of ginsenoside Rg1 against cisplatin-induced hepatic injury through Nrf2 signaling pathway in mice[J].Free Radic Res,2017,51(1):1-13. [10]Ning C,Gao X,Wang C,et al.Protective effects of ginsenoside Rg1 against lipopolysaccharide/d-galactosamine-induced acute liver injury in mice through inhibiting toll-like receptor 4 signaling pathway[J].Int Immunopharmacol,2018(61):266-276. [11]Lin J,Huang HF,Yang SK,et al.The effect of Ginsenoside Rg1 in hepatic ischemia reperfusion(I/R)injury ameliorates ischemia-reperfusion-induced liver injury by inhibiting apoptosis[J].Biomed Pharmacother,2020(129):110398. [12]Gao Y,Chu S,Li J,et al.Anti-inflammatory function of ginsenoside Rg1 on alcoholic hepatitis through glucocorticoid receptor related nuclear factor-kappa B pathway[J].J Ethnopharmacol,2015(173):231-240. [13]Gao Y,Chu SF,Xia CY,et al.Rg1 Attenuates alcoholic hepatic damage through regulating AMP-activated protein kinase and nuclear factor erythroid 2-related f-actor 2 signal pathways[J].J Asian Nat Prod Res,2016,18(8):765-778. [14]Yang S,Kuang G,Jiang R,et al.Geniposide protected hepatocytes from acetaminophen hepatotoxicity by down-regulating CYP 2E1 expression and inhibiting TLR 4/NF-κB signaling pathway[J].Int Immunopharmacol,2019(74):105625. [15]Shen B,Feng H,Cheng J,et al.Geniposide alleviates non-alcohol fatty liver disease via regulating Nrf2/AMPK/mTOR signalling pathways[J].J Cell Mol Med,2020,24(9):5097-5108. [16]Rong YP,Huang HT,Liu JS,et al.Protective Effects of Geniposide on Hepatic Ischemia/Reperfusion Injury[J].Transplant Proc,2017,49(6):1455-1460. [17]Wang J,Zhang Y,Liu R,et al.Geniposide protects against acute alcohol induced liver injury in mice via up-regulating the expression of the main antioxidant enzymes[J].Canadian Journal of Physiology&Pharmacology,2015,93(4):261-267. [18]Yang Y,Ying G,Wu S,et al.In vitro inhibition effects of hepatitis B virus by dandelion and taraxasterol[J].Infectious Agents and Cancer,2020,15(1):44. [19]Zimeng L,Yuanyu L,Riming W,et al.Effects of taraxasterol against ethanol and high-fat diet-induced liver injury by regulating TLR4/MyD88/NF-κB and Nrf2/HO-1 signaling pathways[J].Life Sciences,2020(262):118546. [20]Sang R,Yu Y,Ge B,et al.Taraxasterol from Taraxacum prevents concanavalin A-induced acute hepatic injury in mice via modulating TLRs/NF-κB and Bax/Bc1-2 signalling pathways[J].Artificial Cells,2019,47(1):3929-3937. [21]Xu L,Yu Y,Sang R,et al.Protective Effects of Taraxasterol against Ethanol-Induced Liver Injury by Regulating CYP2E1/Nrf2/HO-1 and NF-κB Signaling Pathways in Mice[J].Oxid Med Cell Longev,2018(2018):8284107. [22]Zhang J,Zhang H,Deng X,et al.Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice[J].Life Sci,2018(192):46-54. [23]Shi L,Zhang S,Huang Z,et al.Baicalin promotes liver regeneration after acetaminophen-induced liver injury by inducing NLRP3 inflammasome activation[J].Free Radic Biol Med,2020(160):163-177. [24]Kim SJ,Lee SM.Effect of baicalin on toll-like receptor 4-mediated ischem-ia/reperfusion inflammatory responses in alcoholic fatty liver condition[J].Toxicology&Applied Pharmacol,2012,258(1):43-50. [25]Lv Z,Wu W,Ge S,et al.Naringin protects against perfluorooctane sulfonate-induced liver injury by modulating NRF2 and NF-κB in mice[J].Int Immunopharmacol,2018(65):140-147. [26]Adil M,Kandhare AD,Ghosh P,et al.Ameliorative effect of naringin in acetaminophen-induced hepatic and renal toxicity in laboratory rats:role of FXR and KIM-1[J].Ren Fail,2016,38(6):1007-1020. [27]Lee HI,Mcgregor RA,Choi MS,et al.Low doses of curcumin protect alcohol-induced liver damage by modulation of the alcohol metabolic pathway,CYP2E1 and AMPK[J].Life Sciences,2013,93(18-19):693-699. [28]Hu RW,Carey EJ,Lindor KD,et al.Curcumin in Hepatobiliary Disease: Pharmacotherapeutic Properties and Emerging Potential Clinical Applications[J].Ann Hepatol,2017,16(6):835-841. [29]Wang B,Gao X,Liu B,et al.Protective effects of curcumin against chronic alc-ohol-induced liver injury in mice through modulating mitochondrial dysfunction and inhibiting endoplasmic reticulum stress[J].Food Nutr Res,2019(1):63. [30]Samuhasaneeto S,Thong-Ngam D,Kulaputana O,et al.Curcumin decreased oxidati-ve stress,inhibited NF-kappaB activation,and improved liver pathology in eth-anol-induced liver injury in rats[J].J Biomed Biotechnol,2009(2009):981963. [31]Ying T,Dan H,Mei-Hua Z,et al.Salvianolic Acid B Inhibits Aβ Generation by Modulating BACE1 Activity in SH-SY5Y-APPsw Cells[J].Nutrients,2016,8(6):333. [32]Zeng W,Shan W,Gao L,et al.Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease[J].Scientific Reports,2015(5):16013. [33]Zhang N,Hu Y,Ding C,et al.Salvianolic acid B protects against chronic alcoh-olic liver injury via SIRT1-mediated inhibition of CRP and ChREBP in rats[J].T-oxicol Lett,2017(267):1-10. [34]Wei J,Zhang L,Liu J,et al.Protective effect of Lycium barbarum polysaccharide on ethanol-induced injury in human hepatocyte and its mechanism[J].T J Food Biochem,2020(3):e13412. [35]魏芬芬,王文娟,贺青华,等.枸杞多糖对小鼠酒精性肝损伤的保护作用及机制研究[J].药物评价研究,2019,42(5):852-857. [36]王莉,叶维佳,吴红静,等.黑果枸杞多糖对大鼠肝损伤的保护研究[J].食品工业科技,2020,41(14):287-290,296. [37]Xiao J,Liong EC,Ching YP,et al.Lycium barbarum polysaccharides protect mice liver from carbon tetrachloride-induced oxidative stress and necroinflammation[J].Journal of Ethnopharmacology,2011,139(2):462-470. [38]Cheng D,Kong H.The effect of Lycium barbarum polysaccharide on alcohol-indu-ced oxidative stress in rats[J].Molecules,2011,16(3):2542-2550. [39]Xiao J,Zhu Y,Liu Y,et al.Lycium barbarum polysaccharide attenuates alcoholi-c cellular injury through TXNIP-NLRP3 inflammasome pathway[J].Int J Biol Macro-mol,2014(69):73-78. [40]Sun ZG,Zhao TT,Lu N,et al.Research Progress of Glycyrrhizic Acid on Antiviral Activity[J].Mini Rev Med Chem,2019,19(10):826-832. [41]Selyutina OY,Polyakov NE.Glycyrrhizic acid as a multifunctional drug carrier - From physicochemical properties to biomedical applications: A modern insight on the ancient drug[J].Int J Pharm,2019(559):271-279. [42]Huo X,Meng X,Zhang J,et al.Hepatoprotective effect of different combinations of 18α-and 18β-Glycyrrhizic acid against CCl4-induced liver injury in rats[J].Biomed Pharmacother,2020(122):109354. [43]Huo X,Sun X,Cao Z,et al.Optimal ratio of 18α-and 18β-glycyrrhizic acid fo-r preventing alcoholic hepatitis in rats[J].Exp Ther Med,2019,18(1):172-178.

相似文献/References:

[1]李珊珊,陈少彬,龚先琼.中药单体治疗非酒精性脂肪性肝病研究进展[J].医学信息,2018,31(21):24.[doi:10.3969/j.issn.1006-1959.2018.21.008]
 LI Shan-shan,CHEN Shao-bin,GONG Xian-qiong.Advances in Research of Traditional Chinese Medicine Monomer in the Treatment of Non-alcoholic Fatty Liver Disease[J].Medical Information,2018,31(05):24.[doi:10.3969/j.issn.1006-1959.2018.21.008]
[2]林思萍,龚先琼.中药单体调控TGF-β1/Smads信号通路抗纤维化的研究[J].医学信息,2019,32(21):30.[doi:10.3969/j.issn.1006-1959.2019.21.011]
 LIN Si-ping,GONG Xian-qiong.Study on Anti-Fibrosis of TGF-β1/Smads Signaling Pathway Regulated by Chinese Medicine Monomer[J].Medical Information,2019,32(05):30.[doi:10.3969/j.issn.1006-1959.2019.21.011]
[3]钟小丽,龚先琼.基于JAK2/STAT3信号通路探讨中药单体治疗肝癌的研究[J].医学信息,2020,33(01):21.[doi:10.3969/j.issn.1006-1959.2020.01.009]
 ZHONG Xiao-li,GONG Xian-qiong.Study on the Treatment of Liver Cancer with Traditional Chinese Medicine Monomer Based on JAK2/STAT3 Signaling Pathway[J].Medical Information,2020,33(05):21.[doi:10.3969/j.issn.1006-1959.2020.01.009]
[4]孙莹莹,龚先琼.中药单体治疗肝细胞癌的研究[J].医学信息,2021,34(09):33.[doi:10.3969/j.issn.1006-1959.2021.09.008]
 SUN Ying-ying,GONG Xian-qiong.Study on the Treatment of Hepatocellular Carcinoma with Chinese Medicine Monomer[J].Medical Information,2021,34(05):33.[doi:10.3969/j.issn.1006-1959.2021.09.008]
[5]陈 玲,龚先琼.中药单体减轻对乙酰氨基酚诱导肝损伤的研究[J].医学信息,2021,34(15):1.[doi:10.3969/j.issn.1006-1959.2021.15.001]
 CHEN Ling,GONG Xian-qiong.Study on the Effect of Chinese Herbal Medicine on Reducing the Liver Injury Induced by Acetaminophen[J].Medical Information,2021,34(05):1.[doi:10.3969/j.issn.1006-1959.2021.15.001]
[6]罗慧英,陈思燕,梁惠卿.中医药防治非酒精性脂肪性肝病的研究进展[J].医学信息,2025,38(10):174.[doi:10.3969/j.issn.1006-1959.2025.10.036]
 LUO Huiying,CHEN Siyan,LIANG Huiqing.Research Progress of Traditional Chinese Medicine in the Prevention and Treatment of Non-alcoholic Fatty Liver Disease[J].Medical Information,2025,38(05):174.[doi:10.3969/j.issn.1006-1959.2025.10.036]
[7]宁 楠,何 静,李利民,等.中药单体靶向缺血性脑卒中相关通路的药理作用研究[J].医学信息,2025,38(15):180.[doi:10.3969/j.issn.1006-1959.2025.15.040]
 NING Nan,HE Jing,LI Limin,et al.Study on the Pharmacological Mechanism of Traditional Chinese Medicine MonomerTargeting Ischemic Stroke-related Pathways[J].Medical Information,2025,38(05):180.[doi:10.3969/j.issn.1006-1959.2025.15.040]
[8]吴丽红,王悦宁,任丽英,等.基于代谢组学探究原花青素改善酒精肝机制[J].医学信息,2026,39(05):8.[doi:10.3969/j.issn.1006-1959.2026.05.002]
 WU Lihong,WANG Yuening,REN Liying,et al.Exploring the Mechanism of Procyanidin in Improving Alcoholic Liver Based on Metabolomics[J].Medical Information,2026,39(05):8.[doi:10.3969/j.issn.1006-1959.2026.05.002]

更新日期/Last Update: 1900-01-01